Fact checked by Marley HallMedically reviewed by Jane Kim, MDFact checked by Marley HallMedically reviewed by Jane Kim, MD It ...

There's one big difference though - Pfizer is seeking a green light for second booster dose of Comirnaty for people aged 60 and over and those in high-risk groups, while Moderna is going for a ...

"The vaccine itself is coupled with an immune system booster, called an adjuvant ... there are also slight differences ...

The CDC's expert panel explores narrowing COVID-19 booster shot guidelines to focus on high-risk groups. Despite concerns ...

Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

MRNA, NVAX Price Action: At the time of publication, Moderna shares were down 5.70% at $31.91 and Novavax shares were down 3.37% at $7.30, according to Benzinga Pro.